Related Experiment Video

Updated: May 8, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer

Dong Han1, Shao-Jun Li, Yan-Ting Zhu

  • 1Respiratory Diseases Research Center, Department of Respiratory Medicine, The Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, China. manxiangli@hotmail.com

Asian Pacific Journal of Cancer Prevention : APJCP
|September 3, 2013
PubMed

Insights

The LKB1/AMPK/mTOR pathway acts as a tumor suppressor. Targeting this pathway, particularly in non-small-cell lung cancer (NSCLC), offers promising therapeutic strategies by modulating cell growth and proliferation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Metabolic Signaling

Background:

  • The link between cancer and metabolism is long-standing.
  • Molecular characterization of the LKB1/AMPK pathway revealed its tumor suppressor role.
  • AMPK regulates cell growth, proliferation, and autophagy via mTOR signaling, which is often deregulated in cancer.

Purpose of the Study:

  • To review the LKB1/AMPK/mTOR signaling pathway.
  • To highlight its protective role in cancer.
  • To explore therapeutic intervention opportunities in non-small-cell lung cancer (NSCLC).

Main Methods:

  • Literature review of molecular characterization of the LKB1/AMPK pathway.
  • Analysis of AMPK's role in regulating mTOR activity.
  • Examination of therapeutic strategies targeting the AMPK/mTOR axis.

Main Results:

  • Somatic mutations in LKB1 are found in certain cancers.
  • The LKB1/AMPK axis remains functional and can be stimulated by drugs like metformin.
  • AMPK/mTOR targeting is a viable strategy for NSCLC treatment.

Conclusions:

  • The LKB1/AMPK/mTOR pathway is a critical tumor suppressor axis.
  • Pharmacological stimulation of AMPK presents therapeutic opportunities.
  • Targeting this pathway is a promising strategy for NSCLC clinical trials.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...